The manufacturer of Kerendia is Bayer [1].
What is Kerendia used for?
Kerendia (finerenone) is a medication prescribed to reduce the risk of sustained kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and stroke in adults with chronic kidney disease (CKD) associated with type 2 diabetes [2].
How does Kerendia work?
Kerendia is a non-steroidal, selective mineralocorticoid receptor antagonist [1, 3]. It works by blocking the harmful effects of excess mineralocorticoid receptor stimulation, which can contribute to kidney and heart damage in individuals with CKD and type 2 diabetes [3].
When did Kerendia become available?
Kerendia received FDA approval in July 2021 [2].
What are the potential side effects of Kerendia?
Common side effects of Kerendia include increased potassium levels in the blood (hyperkalemia), low blood pressure (hypotension), and itching [2]. Patients should have their potassium levels monitored by a healthcare provider before and during treatment [2].
Are there any alternatives to Kerendia for CKD with type 2 diabetes?
While Kerendia targets a specific pathway related to mineralocorticoid receptor activation, other treatment strategies for CKD in patients with type 2 diabetes include managing blood pressure with ACE inhibitors or ARBs, controlling blood glucose levels, and in some cases, GLP-1 receptor agonists or SGLT2 inhibitors [4]. The choice of treatment depends on individual patient factors and physician recommendations.
What is the patent status for Kerendia?
Information regarding the patent status and exclusivity of Kerendia can be found on DrugPatentWatch.com [5].
Who are Bayer's competitors in the CKD market?
Bayer faces competition from companies developing and marketing therapies for chronic kidney disease associated with type 2 diabetes. Competitors offer various classes of drugs, including ACE inhibitors, ARBs, SGLT2 inhibitors, and GLP-1 receptor agonists, which are used to manage the condition and its complications [4].
What clinical data supports Kerendia's efficacy?
Kerendia's approval was based on data from clinical trials, including the FIDELITY program, which demonstrated its effectiveness in reducing the risk of kidney and cardiovascular events in patients with CKD and type 2 diabetes [3].
---
Sources:
[1] https://www.bayer.com/en/us/news/press-releases/bayer-announces-us-fda-approval-kerendia-finerenone-tablets-treatment-chronic-kidney-disease-associated-type-2-diabetes
[2] https://www.kerendia.com/
[3] https://www.bayer.com/en/us/news/press-releases/bayer-celebrates-us-fda-approval-kerendia-finerenone-tablets-treatment-chronic-kidney-disease-associated-type-2-diabetes
[4] https://www.nejm.org/doi/full/10.1056/NEJMra2023752
[5] https://drugpatentwatch.com/